Fig. 4From: First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutationsCharacterization of NRAS variant allele frequency change from baseline in the three groups: partial response (PR), stable disease (SD), and progression disease (PD)Back to article page